Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization
Importance The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III
randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is
needed. Objective To assess the short-term effectiveness of the first dose of the BNT162b2-
vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world
setting. Design, Setting, and Participants This comparative effectiveness study used data
from a 2.6 million-member state-mandated health care system in Israel. Participants …
randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is
needed. Objective To assess the short-term effectiveness of the first dose of the BNT162b2-
vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world
setting. Design, Setting, and Participants This comparative effectiveness study used data
from a 2.6 million-member state-mandated health care system in Israel. Participants …